Peritoneal Metastases (PM) marks an advanced stage of gastrointestinal and ovarian malignancies with an average survival of 6 months at time of diagnosis. Despite the grim prognosis and recent efforts in combating this surgical challenge, current treatments are limited to extensive surgical tumor removal with subsequent intraperitoneal chemotherapy, palliative systemic chemotherapy and a novel palliative method called pressurized intraperitoneal aerosol chemotherapy where a chemo-aerosol is applied onto the peritoneal surface to induce local tumor regression. The poor prognosis is explained by the extensive shortcomings of current treatments, including inhomogeneous drug distribution patterns, limited drug penetration into tumor tissues as well as formation of residual tumor cell clusters following complete PM resection. Thus, it is the goal of this research collection to present and encourage advances in PM treatment
Due to the complexity in treating peritoneal metastasis, an interdisciplinary approach is required to improve current therapeutic options and develop innovative and advanced treatments. This collection is designed as a platform for knowledge transfer. More specifically, this series aims to present recent advances in the surgical approach of treating peritoneal metastasis with an emphasis on the oncologic, medical, technical, and scientific perspective. By means of this collection we aim to extend the current understanding of PM treatment. I believe that the content of the presented studies may offer a potential breakthrough in the field of surgical oncology and impact the clinical setting, and by extension the lives of hundreds of thousands of patients all over the world. Additionally, the knowledge gained from this series may also be extended to other cancer entities. We anticipate a tremendous gain of knowledge with this project and expect to find at least one clinically applicable treatment option with the potential to permanently remiss and possibly cure PM.
We invite experts and investigators in the fields of general surgery, oncology, gynecology, and pharmacology - clinicians as well as basic scientists – who have particular interest in developing treatments for peritoneal metastasis to contribute their work to this collection. The focus of this series is to present an array of innovative PM treatments with a special emphasis on surgical applications. These approaches may include new advances in drug application, device development and innovative surgical techniques. We are interested in original manuscripts, including basic experimental research, device testing, clinical data, as well as reviews which help explore this important topic. The aim of this collection is to fully explore the present state of PM research and to establish an outlook on potential future therapies and how current developments can be applied to improve the care of future patients.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Peritoneal Metastases (PM) marks an advanced stage of gastrointestinal and ovarian malignancies with an average survival of 6 months at time of diagnosis. Despite the grim prognosis and recent efforts in combating this surgical challenge, current treatments are limited to extensive surgical tumor removal with subsequent intraperitoneal chemotherapy, palliative systemic chemotherapy and a novel palliative method called pressurized intraperitoneal aerosol chemotherapy where a chemo-aerosol is applied onto the peritoneal surface to induce local tumor regression. The poor prognosis is explained by the extensive shortcomings of current treatments, including inhomogeneous drug distribution patterns, limited drug penetration into tumor tissues as well as formation of residual tumor cell clusters following complete PM resection. Thus, it is the goal of this research collection to present and encourage advances in PM treatment
Due to the complexity in treating peritoneal metastasis, an interdisciplinary approach is required to improve current therapeutic options and develop innovative and advanced treatments. This collection is designed as a platform for knowledge transfer. More specifically, this series aims to present recent advances in the surgical approach of treating peritoneal metastasis with an emphasis on the oncologic, medical, technical, and scientific perspective. By means of this collection we aim to extend the current understanding of PM treatment. I believe that the content of the presented studies may offer a potential breakthrough in the field of surgical oncology and impact the clinical setting, and by extension the lives of hundreds of thousands of patients all over the world. Additionally, the knowledge gained from this series may also be extended to other cancer entities. We anticipate a tremendous gain of knowledge with this project and expect to find at least one clinically applicable treatment option with the potential to permanently remiss and possibly cure PM.
We invite experts and investigators in the fields of general surgery, oncology, gynecology, and pharmacology - clinicians as well as basic scientists – who have particular interest in developing treatments for peritoneal metastasis to contribute their work to this collection. The focus of this series is to present an array of innovative PM treatments with a special emphasis on surgical applications. These approaches may include new advances in drug application, device development and innovative surgical techniques. We are interested in original manuscripts, including basic experimental research, device testing, clinical data, as well as reviews which help explore this important topic. The aim of this collection is to fully explore the present state of PM research and to establish an outlook on potential future therapies and how current developments can be applied to improve the care of future patients.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.